6 results
Search Results
2. OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19.
- Author
-
Beata Skarzynska, Magdalena, Krol, Bartlomiej, Czajka, Natalia, and Czajka, Lukasz
- Subjects
ANTIVIRAL agents ,AUDIOMETRY ,CHLOROQUINE ,DIAGNOSIS ,HEARING disorders ,OTOACOUSTIC emissions ,AZITHROMYCIN ,OTOTOXICITY ,OSELTAMIVIR ,TOCILIZUMAB ,COVID-19 ,DISEASE risk factors ,SYMPTOMS - Abstract
Copyright of Journal of Hearing Science is the property of Institute of Sensory Organs and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
3. Naphthoquine: A Potent Broad-Spectrum Anti-Coronavirus Drug In Vitro.
- Author
-
Song, Yabin, Deng, Yongqiang, Wang, Huiqiang, Bei, Zhuchun, Gu, Hongjing, Zhao, Hui, Wang, Hong, Zhang, Dongna, Xu, Likun, Wang, Baogang, Li, Yuhuan, and Wang, Hongquan
- Subjects
COVID-19 ,ANTIVIRAL agents ,ANTIMALARIALS ,COVID-19 pandemic ,DRUG efficacy ,DRUGS ,SARS-CoV-2 ,CHLOROQUINE - Abstract
COVID-19 has spread around the world and caused serious public health and social problems. Although several vaccines have been authorized for emergency use, new effective antiviral drugs are still needed. Some repurposed drugs including Chloroquine, Hydroxychloroquine and Remdesivir were immediately used to treat COVID-19 after the pandemic. However, the therapeutic effects of these drugs have not been fully demonstrated in clinical studies. In this paper, we found an antimalarial drug, Naphthoquine, showed good broad-spectrum anti-coronavirus activity. Naphthoquineinhibited HCoV-229E, HCoV-OC43 and SARS-CoV-2 replication in vitro, with IC
50 = 2.05 ± 1.44 μM, 5.83 ± 0.74 μM, and 2.01 ± 0.38 µM, respectively. Time-of-addition assay was also performed to explore at which stage Naphthoquine functions during SARS-CoV-2 replication. The results suggested that Naphthoquine may influence virus entry and post-entry replication. Considering the safety of Naphthoquine was even better than that of Chloroquine, we think Naphthoquine has the potential to be used as a broad-spectrum drug for coronavirus infection. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
- Author
-
BIMONTE, SABRINA, CRISPO, ANNA, AMORE, ALFONSO, CELENTANO, EGIDIO, CUOMO, ARTURO, and CASCELLA, MARCO
- Subjects
ANTIVIRAL agents ,SARS-CoV-2 ,COVID-19 pandemic ,CHLOROQUINE ,CLINICAL trials - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortunately, the antiviral drugs commonly used in clinical practice to treat viral infections, are not applicable to SARS-Cov-2 and no vaccine is available. Thus, it is extremely necessary to identify new drugs suitable for the treatment of the 2019-nCoV outbreak. Different preclinical studies conducted on other coronaviruses suggested that promising clinical outcomes for 2019-nCoV should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. Moreover, clinical trials with these suitable drugs should be performed on patients affected by SARS-Cov-2 to prove their efficacy and safety. Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. The COVID-19 from Neurological Overview.
- Author
-
Acar, Türkan, Demirel, Esra Acıman, Afşar, Nazire, Akçalı, Aylin, Demir, Gülşen Akman, Alagöz, Aybala Neslihan, Mengi, Tuğçe Angın, Arsava, Ethem Murat, Ayta, Semih, Bebek, Nerses, Bilgiç, Başar, Boz, Cavit, Çakar, Arman, Çelebisoy, Neşe, Çevik, Mehmet Uğur, Delen, Firuze, Tekçe, Hacer Durmuş, Ekmekçi, Hakan, Elmal, Ayşe Deniz, and Erdinç, Oğuz Osman
- Subjects
ADULT respiratory distress syndrome treatment ,PNEUMONIA treatment ,PREVENTION of infectious disease transmission ,CORONAVIRUSES ,HYDROXYCHLOROQUINE ,TERMS & phrases ,PERSONAL protective equipment ,AZITHROMYCIN ,PATIENT safety ,INFECTION control ,NUTRITION counseling ,LOPINAVIR-ritonavir ,POLYMERASE chain reaction ,ELECTROENCEPHALOGRAPHY ,HEADACHE ,CHEST X rays ,SEVERITY of illness index ,CHLOROQUINE ,COVID-19 vaccines ,ANTIVIRAL agents ,NEUROLOGICAL disorders ,ELECTROMYOGRAPHY ,NEUROLOGY ,LUNG diseases ,INTENSIVE care units ,DELIRIUM ,NEURORADIOLOGY ,COVID-19 pandemic ,COVID-19 ,PLASMA exchange (Therapeutics) ,CRITICAL care medicine ,CONSCIOUSNESS disorders ,SYMPTOMS - Published
- 2020
- Full Text
- View/download PDF
6. Anti-corona Drugs: Current Scenario.
- Author
-
Fernando, Edwin, Gang, Sishir, Prasad, Narayan, Chaudhary, Arpita Roy, and Agarwal, Sanjay Kumar
- Subjects
ANTIVIRAL agents ,CHLOROQUINE ,EPIDEMICS ,GLUCOCORTICOIDS ,MONOCLONAL antibodies ,AZITHROMYCIN ,TREATMENT effectiveness ,LOPINAVIR-ritonavir ,TOCILIZUMAB ,COVID-19 - Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.